Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Amgen’s Humira Biosimilar Recommended for EMA Approval

XTALKS VITALS NEWS

Biosimilar

If the EMA takes the advice of the CHMP, Amjevita could be approved to treat a number of conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

Share this!

February 1, 2017 | by Sarah Hand, M.Sc.

An advisory committee to the European Medicines Agency (EMA) recently recommended the approval of Amgen’s biosimilar of AbbVie’s Humira. The drug was originally submitted for European approval back in late 2015, with the biosimilar – marketed as Amjevita – approved by the US Food and Drug Administration (FDA) in September of 2016.

If the EMA takes the advice of the CHMP, Amjevita could be approved to treat a number of conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. According to the committee, “studies have shown that Amgevita has comparable quality, safety and efficacy to Humira.”



In addition to Amjevita, the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended the approval of seven other drugs. The committee also announced that Sandoz had withdrawn its application for approval of its biosimilar of Amgen's Neulasta.

Neulasta is not Amgen’s top selling product, however biosimilar competition for the biologic could certainly have an effect on sales of the drug. As Novartis’ generic unit, Sandoz, has withdrawn their application for now, Amgen will have more time to plan for the potential launch of the copycat biologic in the future.

However, Novartis has plans to resubmit the Neulasta biosimilar to the EMA in late 2017. The drugmaker also plans to resubmit the drug for approval by the FDA in 2018.


Keywords: Biosimilar, Biologic, EMA


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.